PSMA Radioligand Therapy in Prostate Cancer-Reference-Cited by-同舟云学术

PSMA Radioligand Therapy in Prostate Cancer

Published:2023-10-25 Issue:1 Volume:49 Page:45-55
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Almeida Ludmila Santiago,de Camargo Etchebehere Elba Cristina Sá,Megías Irene García¹,Calapaquí Terán Adriana K.,Hadaschik Boris,Colletti Patrick M.²,Herrmann Ken,Giammarile Francesco³,Delgado Bolton Roberto C.

Affiliation:

1. Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain

2. Department of Radiology, University of Southern California, Los Angeles, CA, USA

3. Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Vienna, Austria

Abstract

Abstract Diagnosis and treatment of prostate cancer are complex and very challenging, being a major health care burden. The efficacy of radioligand therapy with prostate-specific membrane antigen agents has been proven beneficial in certain clinical indications. In this review, we describe management of prostate cancer patients according to current guidelines, especially focusing on the available clinical evidence for prostate-specific membrane antigen radioligand therapy.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference33 articles.

1. ECCO Essential Requirements for Quality Cancer Care: Prostate cancer;Crit Rev Oncol Hematol,2020

2. Metastatic castration-sensitive prostate cancer: abiraterone, docetaxel, or…;Cancer,2019

3. Metastatic prostate cancer—a review of current treatment options and promising new approaches;Cancers (Basel),2023

4. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT);Eur J Nucl Med Mol Imaging,2023

5. Androgen receptor antagonists for prostate cancer therapy;Endocr Relat Cancer,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Guardians of precision: advancing radiation protection, safety, and quality systems in nuclear medicine;European Journal of Nuclear Medicine and Molecular Imaging;2024-02-06